首页> 美国卫生研究院文献>British Medical Journal >Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study
【2h】

Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study

机译:酶促脱敏治疗季节性变应性鼻炎:双盲随机对照研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective To assess the efficacy of enzyme potentiated desensitisation in the treatment of severe summer hay fever poorly controlled by pharmacotherapy.>Design Double blind randomised placebo controlled parallel group study.>Setting Hospital in Hampshire.>Participants 183 participants aged between 18 and 64 with a history of severe summer hay fever for at least two years; all were skin prick test positive to timothy grass pollen. 90 randomised to active treatment; 93 randomised to placebo.>Interventions Active treatment: two injections of enzyme potentiated desensitisation, given between eight and 11 weeks apart, each comprising 200 Fishman units of β glucuronidase, 50 pg 1,3-cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract (pollen mixes for trees, grasses, and weeds; allergenic fungal spores; cat and dog danders; dust and storage mites) in a total volume of 0.05 ml of buffered saline. Placebo: two injections of 0.05 ml buffered saline solution.>Main outcome measures Proportion of problem-free days; global rhinoconjunctivitis quality of life scores assessed weekly during pollen season.>Results The active treatment group and the placebo group did not differ in the proportion of problem-free days, quality of life scores, symptom severity scores, change in quantitative skin prick provocation threshold, or change in conjunctival provocation threshold. No clinically significant adverse reactions occurred.>Conclusions Enzyme potentiated desensitisation showed no treatment effect in this study.
机译:>目的以评估酶促脱敏在药物治疗控制不佳的严重夏季花粉热中的疗效。>设计双盲随机安慰剂对照平行组研究。>设置汉普郡医院。>参与者年龄在18至64岁之间的183名参与者,至少有两年的夏季花粉热史;所有人对蒂莫西草花粉的皮肤点刺试验均为阳性。 90例随机接受积极治疗; 93随机分配给安慰剂。>干预:积极治疗:两次注射增强酶的脱敏酶,间隔8至11周,每次注射200 Fishman单位的β葡萄糖醛酸苷酶,50 pg 1,3-环己二醇,50 ng硫酸鱼精蛋白和混合吸入的过敏原提取物(树木,草和杂草的花粉混合物;致敏的真菌孢子;猫和狗的皮屑;灰尘和储存螨),总体积为0.05 ml缓冲盐水。安慰剂:两次注射0.05 ml盐溶液。>主要结局指标 >结果:活跃治疗组和安慰剂组在无问题日的比例,生活质量得分,症状严重程度得分,变化方面无差异在定量的皮肤刺激挑衅阈值或结膜挑衅阈值的变化。没有发生临床上显着的不良反应。>结论酶增强的脱敏作用在本研究中未显示治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号